Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662539 · ClinicalTrials.gov registry record · Phase 2
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
A Phase 2 study, sponsored by Zealand Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 493
- Enrollment target
NCT06662539: Completed Phase 2 study, sponsored by Zealand Pharma.
NCT06662539 is a Phase 2 study that has completed, run by Zealand Pharma. The registered enrollment target is 493 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (271% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06662539, a Phase 2 study, has completed, sponsored by Zealand Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 493 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
Primary Outcome
To compare the dose-response of increasing doses of petrelintide versus placebo on body weight, when added as an adjunct to a reduced-calorie diet and increased physical activity after 28 weeks of exposure.
Interventions
- DRUG Placebo
- DRUG Petrelintide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 493 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2026-03-07 |
| Phase | Phase 2 |
What the finished NCT06662539 record still lists
NCT06662539 is an interventional study that assigns participants to a tested intervention. The registered 493 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (271% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06662539 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06662539 about?
NCT06662539 is a clinical study titled "Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities". The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
What is the current status of trial NCT06662539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 493 participants. The study started on 2024-12-09. Estimated completion is 2026-03-07.
What interventions are being tested in trial NCT06662539?
The interventions under investigation include: Placebo (DRUG), Petrelintide (DRUG).
Who is sponsoring clinical trial NCT06662539?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06662539's enrollment target sits among peer trials
493 76th of 2000 higher than 1,925 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- NCT06953089 · 492 participants · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI